Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 7

Integrin alpha 4 beta 7

Brief Information

Name:Integrin alpha-4/beta-7
Target Synonym:LPAM-1,Lymphocyte Peyer s patch Adhesion Molecule 1
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT7-H52W4 Human Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free

Part of Bioactivity data

Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag FreeHuman ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) ELISA bioactivity

Immobilized anti-alpha4 unit,Human IgG4, kappa LC at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) with a linear range of 8-31 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 7,ITGA4&ITGB7


Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Vedolizumab MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio EU Pouchitis Takeda Pharma A/S 2014-05-20 HIV Infections; Inflammatory Bowel Diseases; Pediatric Crohn's disease; Pouchitis; Colitis; Cholangitis, Sclerosing; Pediatric ulcerative colitis; Celiac Disease; Colitis, Ulcerative; Crohn Disease; Melanoma Details
Carotegrast methyl AJM-300 Approved Ea Pharma, Eisai Co Ltd Carogra Japan Colitis, Ulcerative Ea Pharma Co Ltd 2022-03-28 Colitis, Ulcerative Details
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Tysabri, Antegran, Antegren Japan Multiple Sclerosis Biogen Inc 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Stroke; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Myositis, Inclusion Body; Demyelinating Diseases; Crohn Disease Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Multiple Sclerosis, Relapsing-Remitting Details
TRK-170 TRK-170 Toray Industries Inc Details
ABBV-382 Phase 1 Clinical Abbvie Inc HIV Infections Details
PN-10943 PN-10943-A; PN-10943; PN-943 Protagonist Therapeutics Details
Etrolizumab PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 Genentech Inc Details
PTG-100 PTG-100 Protagonist Therapeutics Details
GS-1427 GS-1427 Phase 1 Clinical Gilead Sciences Sl Inflammatory Bowel Diseases Details
MORF-057 MORF-057 Phase 2 Clinical Morphic Therapeutic Inflammatory Bowel Diseases; Colitis, Ulcerative Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message